Why the study?
Increased survival in chronic myeloid leukemia has highlighted cardiovascular complications from baseline risk and tyrosine kinase inhibitor toxicity, necessitating cardiovascular prevention strategies.
Population
Patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Design
Review article
Authors
Loading...
Switching to imatinib/bosutinib, dose reduction, or discontinuation was associated with CV parameter improvement in selected CML patients; leaves open whether these strategies warrant routine adoption.
Cardiovascular risk stratification and monitoring are essential for CML patients treated with TKIs to mitigate the cardiovascular toxicity of these targeted therapies.
Лопіна et al. (2022) studied this question.